[SMC] Novel compound heterozygous mutations in <em>SCN4A</em> as a potential genetic cause contributing to myopathic man

[RSS-Bot]

Heliyon. 2024 Mar 22;10(7):e28684. doi: 10.1016/j.heliyon.2024.e28684. eCollection 2024 Apr 15.

ABSTRACT

BACKGROUND: SCN4A mutations account for a diverse array of clinical manifestations, encompassing periodic paralysis, myotonia, and newly recognized symptoms like classical congenital myopathy or congenital myasthenic syndromes. We describe the initial occurrence of myopathic features mimic with recessive classical CM in a Korean infant presenting with novel compound heterozygous SCN4A mutations. The infant exhibited profound hypotonia after birth, thereby expanding the spectrum of SCN4A-related channelopathy.

METHODS: The genetic analyses comprised targeted exome sequencing, employing a Celemics G-Mendeliome DES Panel, along with Sanger sequencing.

RESULTS: Considering the clinical manifestations observed in the proband, SCN4A variants emerged as the primary contenders for autosomal recessive (AR) congenital myopathy 22a, classic (#620351). Sanger sequencing validated the association of SCN4A variants with the phenotype, affirming the AR nature of the compound heterozygous variants in both the carrier mother (c.3533G > T/p.Gly1178Val) and the father (c.4216G > A/p.Ala1406Thr).

CONCLUSION: Our report emphasizes the association of novel compound heterozygous mutations in SCN4A with myopathic features resembling CM, as supporting by muscle biopsy. It is essential to note that pathogenic SCN4A LoF mutations are exceedingly rare. This study contributes to our understanding of SCN4A mutations and their role in myopathic features mimic with classical CM.

PMID:38571618 | PMC:PMC10988054 | DOI:10.1016/j.heliyon.2024.e28684


Source: https://pubmed.ncbi.nlm.nih.gov/3857161 ... t9+e462414